Designing a Personalized Digital Patient Support Program for Patients Treated With Growth Hormone: Key Design Considerations

Sumaira Malik¹, BSc, MSc, PhD; Clare Moloney¹, BSc, MSc, PhD; Ekaterina Koledova², MD, PhD; Jonathan Reston¹, BA, MSc, PhD; John Weinman³, PhD

¹Atlantis Healthcare, London, United Kingdom
²Endocrinology, Global Medical, Safety and CMO, Merck KGaA, Darmstadt, Germany
³Institute of Pharmaceutical Science, Kings College London, London, United Kingdom

Corresponding Author:
Sumaira Malik, BSc, MSc, PhD
Atlantis Healthcare
Building 5 Chiswick Park
Chiswick High Road
London, W4 5YA
United Kingdom
Phone: 44 2087474360
Email: sumaira.malik@atlantishealthcare.com

Abstract

Background: Recombinant human growth hormone treatment can optimize growth potential; however, optimal outcomes are not always achieved for several reasons, including poor adherence. The overall objective of this project was to design a patient support program to maximize the chances of treatment success for people being treated with somatropin injection. An approach known as the behavior change wheel was used to enhance the development of the patient support program. The behavior change wheel provided a comprehensive framework to support the design of interventions.

Objective: The aim of this paper was to describe how the steps of the behavior change wheel were applied to the development of a patient support program for individuals with growth hormone deficiency undergoing treatment with somatropin.

Methods: We followed a series of steps that align to tenets of the behavior change wheel, namely, a narrative literature review to identify which behaviors needed to change and the potential drivers of and barriers to the behaviors, the selection of an intervention strategy and discrete behavior change techniques, and, finally, intervention specification.

Results: A recent systematic review identified a range of potentially modifiable factors found to have an influence on patient adherence to growth hormone treatment. Insights from the systematic review were used to guide the development of a patient support program. The final design of the patient support program consisted of four elements: (1) a personalization questionnaire to tailor support for each individual, (2) tailored reminder and support SMS text messages, (3) nurse-led phone calls, and (4) Easypod connect, an automated electronic autoinjector drug-delivery device with a transmitter and connection platform for Saizen (somatropin) that allows automatic recording, storage, and transmission of drug-usage data, thus providing insight into suboptimal adherence.

Conclusions: The patient support program that was designed is currently being piloted with patients to assess engagement with the program and determine its impact on patient outcomes. Results from the pilot will be used to further refine the program to ensure it meets user needs.

(J Med Internet Res 2020;22(7):e18157) doi: 10.2196/18157

KEYWORDS
growth hormone; behavior change wheel; somatropin; adherence
Introduction

Recombinant human growth hormone (r-hGH; somatropin) treatment is well established for children and adolescents with growth hormone deficiency [1]. The goal of this treatment is to optimize growth potential, so that the expected target height (based on a normal growth curve for each individual) is achieved by adulthood [2]. Evidence has demonstrated the efficacy of growth hormone treatments to improve growth in children with growth hormone deficiency compared to that of children whose growth hormone deficiency is not treated [3].

The impact of growth hormone deficiency goes beyond reduced growth potential. Research has shown that children with growth hormone deficiency may also experience a psychosocial burden as a result of being physically different from their peers [3,4]. This burden can continue into adulthood, particularly if short stature persists, limiting both personal and professional success [3] as well as potentially having an impact on long-term health, since, as adults, they may also have an increased risk of cardiovascular diseases [5]. With prevalence estimates for growth hormone deficiency from 1.8 to 2.9 per 10,000 in Europe and the United States [6-8], the potential of treatment success to benefit the health economy as well as patients and their families is significant [3].

The overall objective of this project was to design a patient support program to maximize the chances of treatment success for people treated with somatropin by injection. An approach known as the behavior change wheel [9] was used to enhance the development of the patient support program. The behavior change wheel provided a comprehensive framework to support the design of the interventions allowing designers to move from behavior analysis to intervention design using evidence-based techniques and behavior change theory. Central to the behavior change wheel is a framework called the capability, opportunity, motivation, and behavior model (COM-B) [9] (Figure 1). The COM-B model proposes that a person’s health behaviors are driven by a range of factors, which can be grouped under three broad headings: capability, their physical or psychological ability to engage in the behavior, for example, in the context of adherence to medication, factors such as reduced cognitive functioning, mobility problems, or poor treatment comprehension may affect an individual’s ability to understand how to physically administer their treatment; motivation, the internal thoughts and emotions that influence individual decision making in relation to the behavior, for example, beliefs about the need for treatment or the seriousness of the illness may affect how motivated an individual is to try a new treatment or depression as a result of their health condition can reduce their motivation to adhere to a treatment regimen; and opportunity, the external factors which make it possible to engage in the behavior, for example, having a supportive social network and easy access to healthcare resources. In addition to each component influencing medication-related behavior directly, opportunity and capability may affect motivation, and thus also influence behavior in this manner. Jackson and colleagues [10] successfully applied this model to treatment adherence behaviors. While there are similarities in factors for adherence across a patient population, it is important to note that each patient has their own unique needs and set of beliefs that have an impact on their ability to adhere to treatment [11]. Offering personally tailored self-management or adherence interventions to suit their individual needs is the most effective way to ensure patients understand and adopt targeted behaviors, including adherence to r-hGH treatment [11-13]. Tailored interventions and support have also been shown to be more cost-effective [14], an important consideration in the sustainability of support services.

Figure 1. Capability, opportunity, motivation, and behavior framework.

Another crucial component of the behavior change wheel is the selection of appropriate techniques to change behavior. In this paper, we describe how the steps of the behavior change wheel were applied to the development of a patient support program for individuals with growth hormone deficiency who were prescribed somatropin; the duration of individual treatments varies depending on age at time of diagnosis (usually early childhood), and in order to reach full height potential, are continued up to the age when bone growth stops (as the individual reaches adult height). The patient support program was designed to incorporate a large digital component, while also maintaining a strong human support element to personalize
and complement the digital aspects of the intervention. Digital interventions that incorporate a wide range of communication channels such as SMS text messaging, interactive websites, apps, and electronic devices are thought to have great potential for this patient population, given the popularity of digital media among young people [15]; however, despite this, maintaining engagement with digital interventions can be difficult with many studies reporting high levels of dropouts or nonusage [16]. Personalized messaging and multicomponent interventions including both digital and nondigital aspects have been shown to be more effective for behavior change than nontailored messaging and single-component interventions [17]. Yardley et al [16] proposed several general principles and considerations for maximizing engagement with digital behavior-change interventions; they stressed that, most importantly, the intervention should be relevant to the user, ie, it should address an unmet need and should be tailored to the specific situation, needs, and motivations of the user [16]. Utilizing the behavior change wheel and the COM-B framework allowed us to identify the drivers that underlie treatment-related behavior in growth hormone deficiency patients and caregivers, and thus, to create a program with relevant tailored content. Further suggestions [16] included adding a human element to help maintain motivation and ongoing adherence to the digital components of the intervention, ensuring the intervention content was accessible and engaging for people with different levels of health literacy, and taking an iterative approach to intervention development and evaluation to refine the intervention to ensure it would continue to meet user needs. These considerations were also used to guide the design of the patient support program.

**Methods**

**Overview**

We followed a series of steps that were aligned to tenets of the behavior change wheel [9], namely, identifying behaviors that needed to change, identifying the potential drivers of and barriers to the behavior, selecting an intervention strategy and discreet behavior change techniques, and specifying an intervention (Figure 2).

![Behavior change wheel](image)

**Figure 2.** Behavior change wheel.

**Step 1**

A narrative review of the literature was carried out to understand problems associated with treatment management in growth hormone deficiency and to select and specify the target behavior. Literature searches were conducted using CINAHL, Medline, PsychINFO (via EBSCOHost), and the Cochrane Register for Controlled Trials and Systematic Reviews. The following keywords were used: “growth hormone,” “human growth hormone” (MeSH), “child” (MeSH), “adolescent” (MeSH), “patient compliance” (MeSH). Literature was limited to papers written in English and no date restrictions were applied. The reference lists and citations of publications that were identified were also searched for additional papers on the topic.

**Step 2**

Underlying barriers and drivers were defined using insights from a 2018 systematic review [18] looking at the range of potentially modifiable factors that have been found to influence levels of adherence to growth hormone treatment; these factors were grouped according to the COM-B framework. The findings from this review provided direction for selecting the types of interventions that would be needed to effectively target these factors in digital interventions.

**Step 3**

Intervention options were identified using the behavior change wheel, which proposes nine intervention functions: education, persuasion, incentivization, coercion, training, restriction, environmental restructuring, modeling, and enablement. We used APEASE criteria (acceptability, practicability, effectiveness or cost-effectiveness, affordability, safety or side effects, and equity) [19] to guide our selection of the most relevant intervention functions. We also engaged a team of specialists in health psychology with expertise in behavior change.
Step 4
Based on the factors identified by Graham et al [18] and the intervention functions that were selected, a list of relevant behavior change techniques was defined to address each COM-B factor.

Step 5
The full intervention was mapped out, which involved selecting delivery channels (SMS text messages, nurse-led calls, Growlink app), applying the appropriate behavior change techniques to develop content, and designing a personalization questionnaire to tailor the patient experience. In addition, a measurement strategy was designed to evaluate the effectiveness of the intervention.

Table 1. Target behavior description.

| Target behavior | Adherence to somatropin injection |
|-----------------|----------------------------------|
| Who needs to perform the behavior? | Pediatric patients with growth hormone deficiency or their caregiver |
| Where will they do it? | At home |
| How often will they do it? | This will vary depending on individual needs and will be determined by the prescription issued by their health care provider |

Step 2: Behavior Diagnosis
In work relevant to this study, Graham et al [18] conducted a systematic review of pediatric nonadherence to r-hGH treatment using the COM-B framework to identify potentially modifiable factors. Key factors were identified in the review: within the scope of capability—knowledge and understanding of the condition, a lack of understanding of the consequences of missed r-hGH doses, forgetting to administer the medication, or poor administration technique; within the scope of opportunity—ineffective contact with health care providers and the quality of the health care provider–patient relationship, as well as the discomfort and pain associated with daily injections; and within the scope of motivation—the long duration of treatment and dissatisfaction with growth response results.

These findings were largely reflective of the insights gained from our narrative review of growth hormone and adherence literature; they suggested a need to address a range of factors related to patients receiving growth hormone therapy, their caregivers, and growth hormone deficiency and its treatment to ensure optimal adherence.

Steps 3 and 4: Implementation Strategy and Behavior Change Technique Selection
While all nine of the interventions listed in the behavior change wheel were found to be relevant to nonadherence to treatment in growth hormone deficiency, we selected the five intervention functions that we felt were the most relevant and the most appropriate to address within the patient support program; these were education, persuasion, training, modeling, and enablement. This decision was based on a combination of practical considerations such as affordability and cost-effectiveness as well as on behavior change expertise from a team of specialists in health psychology. Table 2 shows the relationship between the factors identified in the COM-B, intervention functions, and selected behavior change techniques. An expanded version of Table 2 including COM-B categories, intervention functions, and intervention content is available in Multimedia Appendix 1.

Results
Step 1: Defining the Problem
A narrative review of the literature on growth hormone deficiency treatments found that despite the potential of r-hGH treatment to optimize growth potential, optimal outcomes were not always achieved; it was proposed that poor adherence was a key contributor to this [2,20,21]. The levels of nonadherence that were reported varied, particularly since definitions and assessment methods differed between studies, but with the proportion of nonadherent patients ranging from 5% to 82% across several indications for which growth hormone therapy is used [2] and with 7% to 71% of patients with growth hormone deficiency found to be nonadherent to treatment [18], it was clear that there was room to improve adherence in this population [2]. Adherence to somatropin injections was selected as a target behavior and outcome for the design of the patient support program. Table 1 further describes the target behaviors.
Table 2. COM-B adherence factors and behavior change techniques.

| Adherence factors                                      | Behavior change techniques                      |
|--------------------------------------------------------|-------------------------------------------------|
| Long duration of treatment                             | • Framing or reframing                          |
| Dissatisfaction with treatment outcome                 | • Self-monitoring                               |
|                                                       | • Framing or reframing                          |
|                                                       | • Reduce negative emotion                       |
| Knowledge and understanding of condition               | • Credible source                               |
|                                                       | • Information on health consequences            |
| Discomfort or pain from daily injection                | • Instruction of how to perform the behavior    |
|                                                       | • Problem solving                               |
|                                                       | • Verbal persuasion of capability               |
|                                                       | • Reduce negative emotion                       |
| Lack of understanding of the consequences of missed doses | • Information on health consequence             |
|                                                       | • Salience of consequences                      |
| Forgetting                                             | • Feedback on behavior                          |
|                                                       | • Self-monitoring                               |
|                                                       | • Prompts or cues                               |
|                                                       | • Problem solving                               |
| Health care provider–patient communication            | • Demonstration of the behavior                 |
|                                                       | • Problem solving                               |
|                                                       | • Verbal persuasion of capability               |
| Poor injection technique                               | • Instruction on how to perform the behavior    |
|                                                       | • Demonstration of the behavior                 |

Step 5: Mapping the Design of the Patient Support Program

Overview

Based on these findings, as well as on insights from digital behavior change intervention design principles and behavior change theory, a multicomponent digital patient support program was designed for patients receiving treatment with somatropin injection (see Table 2 for example content). The patient support program consists of four components: personalization screening, SMS text messages, nurse-led phone calls, and an eHealth component.

Personalization Screening Questionnaire

A set of personalization questions was created based on the drivers of adherence that were identified in step 2. The design includes different questions for caregivers and patients, allowing for support to be tailored to both or either, depending on who is taking part in the patient support program. Patients and caregivers will be asked to complete the screening questionnaire when they join the patient support program and will be rescreened every 12 weeks. This is to ensure that support can be flexible to changing needs and to allow for review of intervention effectiveness by monitoring changes to beliefs and to support needs. The personalization screening questionnaire will be used to determine topic priority and focus of the SMS text messages and of the nurse-led components of the program.

SMS Text Messages

These include medication reminders as well as tailored intervention messages to address adherence factors that have been identified as important through the personalization screening questionnaire.

Nurse-Led Phone Calls

Patient support program nurses will be trained to deliver brief, evidence-based interventions to address the adherence barriers that were identified. The content and order of these telephone calls will be tailored to the needs of each individual patient or caregiver based on personalization screening questionnaire responses.

eHealth Component

The Easypod is an automated electronic autoinjector drug-delivery device with a transmitter and web-based connection platform for Saizen (somatropin) that automatically inserts a needle and delivers a preset dose to the patient. The device allows automatic recording, storage, and transmission of drug adherence data, thus providing insight into suboptimal adherence (through dose frequency) and its resulting effect on growth. Patients and caregivers can access the information via a patient app (Growlink), and physicians and nurses can access the information via the web-based Easypod connect platform.
Discussion

Principal Findings

The purpose of this paper was to describe the development of a patient support program aimed at supporting patients who have been prescribed Saizen in order to maximize their growth potential. A structured approach based on the behavior change wheel and the COM-B framework was used to identify the drivers of behavior and to systematically explore how these could be addressed through a pharma-funded patient support program.

The final design of the patient support program incorporated a patient-centric digital component featuring an online app linked to the injection device and frequent SMS text message delivery. The digital platform offers a convenient method for patients, caregivers, and health care providers to interact, to share, and to review adherence data for each patient. The addition of SMS text messaging allows adherence reminder messages and intervention content that was designed to address nonadherence to be sent to individual patients. SMS text messages have been successfully used in behavior change interventions as both reminders for appointments or for treatments [22], as well as to deliver interventions to change patient beliefs and to improve adherence [2]. A 2011 meta-analysis [23] of the efficacy of SMS text message reminders showed that they were effective across all age groups; there were also no differences in effect based on the timing of the messages or the rate that the messages were sent [23]. Messaging interventions have been shown to improve adherence to medications across a wide variety of clinical applications including asthma, antiretroviral treatments, and schizophrenia, in both adult and pediatric populations [22,24,25]. The effect of personalized messaging on behavior has also been shown to be more effective than that of nontailored messaging [17]. In line with the recommendations of Yardley et al [16], tailored content may also help increase engagement with digital interventions. In this patient support program, tailored content was achieved through a personalization screening questionnaire designed to determine the content and sequence of SMS text messages and nurse-led phone calls for delivery of the intervention; the online app was also designed to provide personalized adherence feedback.

Personalized telephone calls with a specialist nurse add a human element to the patient support program which may help to support continued engagement. Evidence has shown that nurses can successfully be trained to use behavior change techniques and to implement motivational interviewing techniques by a simple, brief course [26,27]. Nurse-led calls that implement motivational interviewing principles and that teach behavior change techniques have been shown to result in meaningful behavior change [28,29]. In addition, telephone-based support has been shown to be an effective delivery channel for promoting behavior change across different health conditions such as smoking cessation, increasing physical activity, and improving diet [30], as well as demonstrating a positive impact on treatment adherence [31,32]. Research has also shown that, in general, multicomponent interventions are more successful in having an impact on behavior than single-component interventions are [33]. Thus, the nurse-led coaching phone calls are likely to enhance and complement the support provided through the digital components.

Another important consideration for any patient support program is the level of health literacy. Yardley et al [16] argued that digital behavior change interventions should be accessible and engaging for people with low levels of health literacy and should also be acceptable and usable for those with higher levels of health literacy. All content that was developed for the patient support program was reviewed by an experienced health psychologist and writer, and by a creative team to ensure the pitch, tone, and level was appropriate for the range of health literacy levels in the patient group.

Future Work

Our patient support program will be piloted with the aim of establishing its perceived acceptability and usefulness. The evaluation of the pilot patient support program will be conducted using an observational (real-world evidence) within-subjects design. Three categories of data will be captured: operational data, user experience data, and impact data. The primary outcome will be patient perception of the helpfulness of the patient support program. Secondary outcomes will include change in adherence and change in quality of life over the course of the patient support program, and multiple regression modeled predictors of these outcomes. Finally, data will be captured to identify ways in which various components of the patient support program could be improved, in line with the principles of continuous development in patient support program design, behavior change technique, and digital interventions proposed by Michie et al [34]. These data will be captured during routine operation via the patient support program (such as number and length of sessions), supplementary behavior-changing customer relationship management, and follow-up evaluation surveys.

Strengths and Limitations

The patient support program was developed using a systematic and structured approach, by drawing on relevant literature, and using appropriate evidence-based behavior change theories and frameworks. To the best of our knowledge, this represents a novel approach to the development of patient support programs in growth hormone deficiency; however, despite this, the use of the behavior change wheel inevitably required that the intervention development team make subjective and practical decisions regarding the most appropriate strategies and delivery channels. Since there was limited data on the most appropriate intervention channels and implementation of behavior change techniques for this patient population; the team drew from their own experience working in this patient population to guide some of these decisions.

The first part of the design process involved a narrative review of relevant literature. While this review captured a large volume of relevant literature, the methods were not exhaustive. Key search terms were provided, but to ensure that all relevant papers had been captured in an entirely reproducible format, a full systematic review was required. To be efficient, this paper focused, where possible, on meta-analyses and systematic
reviews such as [18] which partially summarized large quantities of the literature.

Conclusions
Using the approach outlined by the behavior change wheel, a multicomponent patient support program for patients with growth hormone deficiency (and their caregivers) to achieve their growth potential through adherence using the Easypod connect platform was developed. By incorporating personalization screening questionnaires into the patient support program, personalized intervention messages and nurse-led phone support can be offered to patients. Work is underway to implement and validate the patient support program, to establish whether it can improve adherence in a real-world setting.

Acknowledgments
This work was funded by Merck KGaA. Editorial support was provided by Jorge Cancela who, at the time of writing, was an employee of Ares Trading (an affiliate of Merck KGaA) and by Steven Goodrick of inScience Communications, Springer Healthcare Ltd.

Conflicts of Interest
JR and SM are employees of Atlantis Healthcare and received funding from Merck KGaA to carry out this work. At the time of writing, CM was an employee of Atlantis Healthcare and received funding from Merck KGaA to carry out this work. JW is a consultant to Atlantis Healthcare and received funding from Merck KGaA to carry out this work. EK is an employee of Merck KGaA.

Multimedia Appendix 1
Expanded Table 2.
[DOC File, 39 KB-Multimedia Appendix 1]

References
1. Al Herbish AS, Al Alwan I, Al Mutair A, Al Twaim A, Al Agha A, Deeb A, et al. Growth hormone therapy and treatment outcomes: current clinical practice of the Gulf Cooperation Council. Expert Rev Endocrinol Metab 2014 Jul;9(4):319-325. [doi: 10.1586/17446651.2014.921115] [Medline: 30763992]
2. Fisher BG, Acerini CL. Understanding the growth hormone therapy adherence paradigm: a systematic review. Horm Res Paediatr 2013;79(4):189-196 [FREE Full text] [doi: 10.1159/000350251] [Medline: 23635979]
3. Takeda A, Cooper K, Bird A, Baxter L, Frampton G, Gospodarevskaya E, et al. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation. Health Technol Assess 2010 Sep;14(42):1-209, iii. [doi: 10.3310/hta14420] [Medline: 20849734]
4. Brod M, Alolga SL, Beck JF, Wilkinson L, Højbjerre L, Rasmussen MH. Understanding burden of illness for child growth hormone deficiency. Qual Life Res 2017 Jul;26(7):1673-1686 [FREE Full text] [doi: 10.1007/s11136-017-1529-1] [Medline: 28247315]
5. Bates AS, Van't Hoff W, Jones PJ, Clayton RN. The effect of hypopituitarism on life expectancy. J Clin Endocrinol Metab 1996 Mar;81(3):1169-1172. [doi: 10.1210/jcem.81.3.8772595] [Medline: 8772595]
6. Lindsay R, Feldkamp M, Harris D, Robertson J, Rallison M. Utah Growth Study: growth standards and the prevalence of growth hormone deficiency. J Pediatr 1994 Jul;125(1):29-35. [doi: 10.1016/s0022-3476(94)70117-2] [Medline: 8021781]
7. Thomas M, Massa G, Craen M, de Zegher F, Heinrichs C, et al. Prevalence and demographic features of childhood growth hormone deficiency in Belgium during the period 1986-2001. Eur J Endocrinol 2004 Jul;151(1):67-72. [doi: 10.1530/eje.0.1510067] [Medline: 15248824]
8. Vimpani GV, Vimpani AF, Lidgard GP, Cameron EH, Farquhar JW. Prevalence of severe growth hormone deficiency. Br Med J 1977 Aug 13;2(6084):427-430 [FREE Full text] [doi: 10.1136/bmj.2.6084.427] [Medline: 890325]
9. Michie S, van SMM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci 2011;6:42 [FREE Full text] [doi: 10.1186/1748-5908-6-42] [Medline: 21530547]
10. Jackson C, Eliasson L, Barber N, Weinman J. Applying COM-B to medication adherence: a suggested framework for research and interventions. Eur Health Psychol 2014;16(1):7-17 [FREE Full text]
11. Haverkamp F, Gasteiger C. A review of biopsychosocial strategies to prevent and overcome early-recognized poor adherence in growth hormone therapy of children. J Med Econ 2011;14(4):448-457. [doi: 10.3111/13696998.2011.590829] [Medline: 21651428]
12. Cockle-Hearne J, Faithfull S. Self-management for men surviving prostate cancer: a review of behavioural and psychosocial interventions to understand what strategies can work, for whom and in what circumstances. Psychooncology 2010 Sep;19(9):909-922. [doi: 10.1002/pon.1657] [Medline: 20119934]
13. Lorig KR, Holman H. Self-management education: history, definition, outcomes, and mechanisms. Ann Behav Med 2003 Aug;26(1):1-7. [Medline: 12867348]
14. Radhakrishnan K. The efficacy of tailored interventions for self-management outcomes of type 2 diabetes, hypertension or heart disease: a systematic review. J Adv Nurs 2012 Mar;68(3):496-510. [doi: 10.1111/j.1365-2648.2011.05860.x] [Medline: 22010971]

15. Child J, Davies C, Frost K, McDermid E, Piccock E, Weinman J, et al. Managing paediatric growth disorders: integrating technology into a personalised approach. J Clin Res Pediatr Endocrinol 2019 Nov 20 [FREE Full text] [doi: 10.4274/jcrpe.galenos.2019.2019.0153] [Medline: 31744271]

16. Yardley L, Spring BJ, Riper H, Morrison LG, Crane DH, Curtis K, et al. Understanding and promoting effective engagement with digital behavior change interventions. Am J Prev Med 2016 Nov;51(5):833-842. [doi: 10.1016/j.amepre.2016.06.015] [Medline: 27755683]

17. Fjeldsoe BS, Marshall AL, Miller YD. Behavior change interventions delivered by mobile telephone short-message service. Am J Prev Med 2009 Feb;36(2):165-173. [doi: 10.1016/j.amepre.2008.09.040] [Medline: 19135907]

18. Graham S, Weinman J, Ayeung V. Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: a systematic review. Horm Res Paediatr 2018;90(4):221-227 [FREE Full text] [doi: 10.1159/000493211] [Medline: 30522126]

19. Michie S, Atkins L, West R. The Behaviour Change Wheel: A Guide To Designing Intervention. London: Silverback Publishing; 2014:1-329.

20. Aydın BK, Aycan Z, Sıklar Z, Berberoğlu M, Ocal G, Cetinkaya S, et al. Adherence to growth hormone therapy: results of a multicenter study. Endocr Pract 2014 Jan;20(1):46-51. [doi: 10.4158/EP13194.0R] [Medline: 24013997]

21. Cutfield WS, Derraik JGB, Gunn AJ, Reid K, Delany T, Robinson E, et al. Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One 2011 Jan 31;6(1):e16223 [FREE Full text] [doi: 10.1371/journal.pone.0016223] [Medline: 21305004]

22. Free C, Phillips G, Watson L, Galli L, Felix L, Edwards P, et al. The effectiveness of mobile-health technologies to improve health care service delivery processes: a systematic review and meta-analysis. PLoS Med 2013 Jan;10(1):e1001363 [FREE Full text] [doi: 10.1371/journal.pmed.1001363] [Medline: 23458994]

23. Boksmati N, Butler-Henderson K, Anderson K, Sahama T. The effectiveness of SMS reminders on appointment attendance: a meta-analysis. J Med Syst 2016 Apr;40(4):90. [doi: 10.1007/s10916-016-0452-2] [Medline: 26852337]

24. Lau PWC, Lau EY, Wong DP, Ransdell L. A systematic review of information and communication technology-based interventions for promoting physical activity behavior change in children and adolescents. J Med Internet Res 2011;13(3):e48 [FREE Full text] [doi: 10.2196/jmir.1533] [Medline: 21749967]

25. Granholm E, Ben-Zeev D, Link PC, Bradshaw KR, Holden JL. Mobile Assessment and Treatment for Schizophrenia (MATS): a pilot trial of an interactive text-messaging intervention for medication adherence, socialization, and auditory hallucinations. Schizophr Bull 2012 May;38(3):414-425 [FREE Full text] [doi: 10.1093/schbul/sbr155] [Medline: 22080492]

26. Madson MB, Loignon AC, Lane C. Training in motivational interviewing: a systematic review. J Subst Abuse Treat 2009 Jan;36(1):101-109. [doi: 10.1016/j.jsat.2008.05.005] [Medline: 18657936]

27. Mannix KA, Blackburn IM, Garland A, Gracie J, Moorey S, Reid B, et al. Effectiveness of brief training in cognitive behaviour therapy techniques for palliative care practitioners. Palliat Med 2006 Sep;20(6):579-584. [doi: 10.1177/0269216306071058] [Medline: 17060250]

28. Cook PF, Emilozzi S, El-Hajj D, McCabe MM. Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study. Patient Educ Couns 2010 Nov;81(2):182-186. [doi: 10.1016/j.pec.2009.12.010] [Medline: 20079598]

29. McBride CM, Rimer BK. Using the telephone to improve health behavior and health service delivery. Patient Educ Couns 1999 May;37(1):3-18. [doi: 10.1016/S0165-5176(99)00004-8] [Medline: 10640115]

30. Bricker JB, Mann SL, Marek PM, Liu J, Peterson AV. Telephone-delivered acceptance and commitment therapy for adult smoking cessation: a feasibility study. Nicotine Tob Res 2010 Apr;12(4):454-458. [doi: 10.1093/ntr/ntq002] [Medline: 20424177]

31. Mohr DC, Likosky W, Bertagnolli A, Goodkin DE, Van DWJ, Dwyer P, et al. Telephone-administered cognitive-behavioral therapy for the treatment of depressive symptomatology in multiple sclerosis. J Consult Clin Psychol 2000 Apr;68(2):356-361. [doi: 10.1037/0022-006X.68.2.356] [Medline: 10780138]

32. Turner AP, Sloan AP, Kivilahna DR, Haselkorn JK. Telephone counseling and home telehealth monitoring to improve medication adherence: results of a pilot trial among individuals with multiple sclerosis. Rehabil Psychol 2014 May;59(2):136-146. [doi: 10.1037/a0036322] [Medline: 24708232]

33. Del Pino-Sedeño T, Peñate W, de Las Cuevas C, Valcarcel-Nazco C, Fumero A, Serrano-Pérez PG, et al. Effectiveness and cost-effectiveness of a multicomponent intervention to improve medication adherence in people with depressive disorders - MAPDep: a study protocol for a cluster randomized controlled trial. Patient Prefer Adherence 2019;13:309-319 [FREE Full text] [doi: 10.2147/PPA.S172963] [Medline: 30863020]

34. Michie S, Yardley L, West R, Patrick K, Greaves F. Developing and evaluating digital interventions to promote behavior change in health and health care: recommendations resulting from an international workshop. J Med Internet Res 2017 Jun 29;19(6):e232 [FREE Full text] [doi: 10.2196/jmir.7126] [Medline: 28663162]
Abbreviations

**COM-B:** capability, opportunity, motivation, and behavior model

**MeSH:** medical subject heading (index term)

**r-hGH:** recombinant human growth hormone

© Sumaira Malik, Clare Moloney, Ekaterina Koledova, Jonathan Reston, John Weinman. Originally published in the Journal of Medical Internet Research (http://www.jmir.org), 29.07.2020. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on http://www.jmir.org/, as well as this copyright and license information must be included.